TW200848371A - Method of recovering Cd-112 isotope - Google Patents
Method of recovering Cd-112 isotope Download PDFInfo
- Publication number
- TW200848371A TW200848371A TW96121583A TW96121583A TW200848371A TW 200848371 A TW200848371 A TW 200848371A TW 96121583 A TW96121583 A TW 96121583A TW 96121583 A TW96121583 A TW 96121583A TW 200848371 A TW200848371 A TW 200848371A
- Authority
- TW
- Taiwan
- Prior art keywords
- cadmium
- solution
- isotope
- recovering
- precipitate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000002244 precipitate Substances 0.000 claims abstract description 20
- PLLZRTNVEXYBNA-UHFFFAOYSA-L cadmium hydroxide Chemical compound [OH-].[OH-].[Cd+2] PLLZRTNVEXYBNA-UHFFFAOYSA-L 0.000 claims abstract description 14
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 3
- CXKCTMHTOKXKQT-UHFFFAOYSA-N cadmium oxide Inorganic materials [Cd]=O CXKCTMHTOKXKQT-UHFFFAOYSA-N 0.000 claims abstract 3
- CFEAAQFZALKQPA-UHFFFAOYSA-N cadmium(2+);oxygen(2-) Chemical compound [O-2].[Cd+2] CFEAAQFZALKQPA-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000012670 alkaline solution Substances 0.000 claims abstract 2
- 238000001354 calcination Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 10
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 9
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052793 cadmium Inorganic materials 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 6
- WUPHOULIZUERAE-UHFFFAOYSA-N 3-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)CCC1CCCO1 WUPHOULIZUERAE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052980 cadmium sulfide Inorganic materials 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000007747 plating Methods 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000031709 bromination Effects 0.000 claims 1
- 238000005893 bromination reaction Methods 0.000 claims 1
- 230000005611 electricity Effects 0.000 claims 1
- 238000005242 forging Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000012047 saturated solution Substances 0.000 claims 1
- 239000012085 test solution Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000009713 electroplating Methods 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 abstract 1
- 229940039231 contrast media Drugs 0.000 abstract 1
- 150000004679 hydroxides Chemical class 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000004064 recycling Methods 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 description 5
- KPWJBEFBFLRCLH-UHFFFAOYSA-L cadmium bromide Chemical compound Br[Cd]Br KPWJBEFBFLRCLH-UHFFFAOYSA-L 0.000 description 4
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 4
- 229940055742 indium-111 Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QLTINGPHXJSLHC-UHFFFAOYSA-N O(Cl)Cl.[Ar] Chemical compound O(Cl)Cl.[Ar] QLTINGPHXJSLHC-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- -1 inInC13 Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Manufacture And Refinement Of Metals (AREA)
Abstract
Description
200848371 九、發明說明: 【發明所屬之技術領域】 本發明係提供一種回收鎘-112同位素之方法,特 別是本發明係將鎘-112靶材之化學分離液或電鍍液之 剩液藉由與氫氧化物反應使生成氫氧化鎘沉澱物,再 經由過濾漂洗回收鎘-112同位素。 【先前技術】 銦-111放射性同.位素之核子特性係捕捉電子放出 兩個加馬射線特性能譜,由於其半衰期短且能量適中 己廣泛應用於核醫單光子放射電腦斷層掃描(Single Photon Emission Computerized Tomography, SPECT ) 診斷人體器t病變與生理功能研究。 銦-111 之標幟化合物如:inInC13,lnIn-bleomysin 及mIn-DTPA (奥克肽哼)可用於鑑定器官局部腫瘤, 而inIn-Oxine脂溶性錯化合物可標幟於白血球進行膿 腫之造影及診斷炎症等病灶,而1πΙη與單株抗體、血 小板、球蛋白或巨大分子yt-PA ( recombinant tissue plasminogen activator)及 Fab、(Fab')2 (immunoglobulin fragments)等形成之錯化合物則為最新發展具有極佳 應用潛力之造影劑,可掃描出心肌梗塞與血栓之正確 位置及進行凝血酵素與腎功能等相關生理研究。 銦-111同位素之主要生產途徑有112Cd(p,2n)、 inCd(p,n)、natCd(p,xn)、110Cd(d,n)及 109Ag(a,2n)等, 5 200848371 其中以第一種方式利用高豐度濃縮112Cd(970/〇)固體靶 於適當靶厚(〜ΙΟΟμηι)及質子束能量卜22MeV)條件下 可獲得luIn最大產率。 於核醫製藥中心,在迴旋加速器製作核醫藥物奥 克肽噚(銦-111),我國因無法產製類似之同位素,每年 生產核醫藥物奥克肽噚(銦-1U),所需濃縮鎘-112同位 素、’,需抑賴進口,且獲得不易。故,一般習用者係 無法符合使用者於實際使用時之所需。 【發明内容】 本發明之主要目的係在於提供一可節省原料費用 =降低成本之回收鎘_112同位素之方法,而且回收率 高,得到純度高之鎘-112同位素。 為達上述之目的,本發明係提供一回收鎘_112同 位素之方法,係將一鎘-112靶材電鍍液之剩液中加入 一硫化物溶液,使其產生一硫化鎘沉澱物,再利用一 鹽酸將該硫化鎘沉澱物溶解形成一氣化鎘溶液,接著 加入氫氧化物溶液混合產生一氫氧化鎘沉殿物,最 後將該氫氧化鎘沉澱物進行過濾及漂洗以回收鎘_112 同位素。 另,本發明亦可先將一鎘-112靶材化學分離液與 一溴化鎘溶液混合形成一混合液,再取一氫氧化物溶 液加入該混合液中混合攪拌產生一氫氧化鎘沉澱物, 最後將該氫氧化鎘沉澱物經由過濾及漂洗以回收编 200848371 • 112同位素。 【實施方式】 請參閱『第1及第2圖』所示,係為本發明之第 一實施例流程示意圖及本發明之第二實施例流程示意 圖。如圖所示:本發明係為一種回收鎘“12同位素之 方法’可由録·112㈣㈣液之剩液或鑛·112乾材化 學分離液回收錯_112同位素,其中,利用鑛·112乾材 電鍍液之剩液進行回收之方法係至少包括下列步驟: 步驟(A 1 )產生硫化鎘沉殿物工工··將一硫化 物溶液加入一鎘_112靶材電鍍液之剩液中產生一硫化 録沉㈣’其中,該硫化物溶液係可為硫化納溶液、 …π步驟(B 1 )形成氣钱溶液} 2 :將該硫化録 沉澱物加入一鹽酸溶解以形成一氣化鎘溶液。 步驟(C 1 )產生氩氧化鎘沉澱物工3 :將該氣 =鎘溶液加入一意氧化物溶液混合產生一氫氧化鎘沉 澱物,其中,亥氫氧化物溶液係可為氫氧化卸溶液或 是氫氧化鈉溶液。 步驟(D 1 )回收鎘_112同位素工4 :將該氫氧 化鑛沉澱物移入半自動化真空過滤系統’進作過渡及 漂洗以回收鎘-112同位素。 另本發明亦h供利用錫_112 |&材化學分離液進 行回收之方法,係至少包括下列步驟: 200848371 步驟(A 2 )形成混合液2 1 :將鎘-112靶材化 學分離液與溴化鎘溶液混合形成一混合液。 步驟(B 2 )產生氫氧化鎘沉澱物2 2 ··取一氫 氧化物溶液加入上述混合液中混合攪拌,使其產生一 氫氧化鎘沉澱物,其中,該氫氧化物溶液係可為氫氧 化鉀溶液或是氫氧化鈉溶液。 步驟(C 2 )形成鎘-112同位素2 3 :將該氫氧 化鎘沉殿物移入半自動化真空過濾、系統,進行過遽及 》示洗以回收鑛j -112同位素。 從上述兩種方法所回收之鑛-112同位素係可經鍛 燒成為一固態氧化鑛,或利用氰化物溶液與驗性溶液 溶解形成一鎘-112靶材電鍍液,該鎘-112同位素之回 收率可達98%以上,純度亦可達99%左右,且易儲存。 綜上所述,本發明之回收鎘_112同位素之方法, 係回收再循環使用鎘-112同位素,使其回收率及純度 達98%以上,亦可節省採購原料費用及降低核醫製藥 成本,進而使本發明之産生能更進步、更實用、更符 δ使用者之所需,確已符合發明專利申請之要件。 惟以上所述者,僅為本發明之較佳實施例而已, 當不能以此限定本發明實施之範圍;故,凡依本發明 申請專利範圍及發明說明書内容所作之簡單的等效變 化與修飾,皆應仍屬本發明專利涵蓋之範圍内。 200848371 【圖式簡單說明】 第1圖 ,係本發明之第一實施例流程示意圖。 第2圖,係本發明之第二實施例流程示意圖。 【主要元件符號說明】 步驟(A 1 )〜(D 1 ) 1 1〜1 4 步驟(A2)〜(C2)21〜23200848371 IX. Description of the Invention: [Technical Field] The present invention provides a method for recovering cadmium-112 isotope, and in particular, the present invention uses a chemical separation liquid or a plating solution of a cadmium-112 target to The hydroxide reaction produces a cadmium hydroxide precipitate which is then recovered by filtration to recover the cadmium-112 isotope. [Prior Art] The nucleon characteristic of indium-111 radioactive isotopes is the capture of electrons to release two additional gamma ray performance spectra. Due to its short half-life and moderate energy, it has been widely used in nuclear medicine single photon emission computed tomography (Single Photon). Emission Computerized Tomography, SPECT ) Diagnose t disease and physiological function of human body. Indium-111 flag compounds such as: inInC13, lnIn-bleomysin and mIn-DTPA (Octopeptide) can be used to identify local tumors, while inIn-Oxine fat-soluble compounds can be labeled in white blood cells for angiography and diagnosis of abscesses. Inflammation and other lesions, and 1πΙη and the monogenic antibodies, platelets, globulins or yt-PA (recommended tissue plasminogen activator) and Fab, (Fab') 2 (immunoglobulin fragments) and other compounds are the latest developments The contrast agent with good application potential can scan the correct position of myocardial infarction and thrombus and carry out related physiological research on thrombin and renal function. The main production pathways of indium-111 isotope are 112Cd(p, 2n), inCd(p, n), natCd(p, xn), 110Cd(d, n) and 109Ag(a, 2n), etc., 5 200848371 One way to obtain a maximum yield of luIn using a high abundance 112Cd (970/〇) solid target at a suitable target thickness (~ΙΟΟμηι) and proton beam energy 22 MeV). In the nuclear medicine and pharmaceutical center, the nuclear medicine oktoprost (Indium-111) was produced in a cyclotron. In China, it is impossible to produce similar isotopes, and the annual production of nuclear medicine Okpitonium (Indium-1U) is required. Cadmium-112 isotope, ', need to rely on imports, and access is not easy. Therefore, the general practitioners cannot meet the needs of the user in actual use. SUMMARY OF THE INVENTION The main object of the present invention is to provide a method for recovering cadmium-112 isotope which can save raw material cost = reduce cost, and has high recovery rate, and obtain cadmium-112 isotope with high purity. In order to achieve the above object, the present invention provides a method for recovering cadmium-112 isotope by adding a sulphide solution to a residual solution of a cadmium-112 target plating solution to produce a cadmium sulfide precipitate, and then utilizing The cadmium sulfide precipitate is dissolved by a hydrochloric acid to form a cadmium sulfide solution, and then mixed with a hydroxide solution to produce a cadmium hydroxide precipitate. Finally, the cadmium hydroxide precipitate is filtered and rinsed to recover the cadmium-112 isotope. In addition, the present invention may also firstly mix a cadmium-112 target chemical separation liquid with a cadmium bromide solution to form a mixed solution, and then add a hydroxide solution to the mixed solution and mix and stir to produce a cadmium hydroxide precipitate. Finally, the cadmium hydroxide precipitate was filtered and rinsed to recover the 200848371 • 112 isotope. [Embodiment] Please refer to the "1st and 2nd drawings" for a flow chart of a first embodiment of the present invention and a schematic flow chart of a second embodiment of the present invention. As shown in the figure: the present invention is a method for recovering cadmium "12 isotope" from the residual liquid of the 112 (4) (four) liquid or the chemical separation liquid of the dry material of 112 dry material, which is used to recover the wrong _112 isotope. The method for recovering the residual liquid of the liquid comprises at least the following steps: Step (A 1 ) Producing a cadmium sulfide sulphide material workmanship · Adding a sulphide solution to a residual solution of a cadmium _112 target plating solution to produce a vulcanization Recording (4) 'wherein, the sulfide solution can be a sodium sulfide solution, ... π step (B 1 ) to form an air money solution} 2: The sulfide precipitate is dissolved in monohydrochloric acid to form a vaporized cadmium solution. C 1 ) generating argon oxychloride precipitates 3: mixing the gas=cadmium solution into a monolithic oxide solution to produce a cadmium hydroxide precipitate, wherein the hexa hydroxide solution can be a hydrolytic solution or a hydroxide Sodium solution. Step (D 1 ) recovery of cadmium_112 isotope 4: The hydroxide ore deposit is transferred to a semi-automatic vacuum filtration system for transition and rinsing to recover the cadmium-112 isotope. _112 |& The method for recovering the separation liquid comprises at least the following steps: 200848371 Step (A 2 ) forming a mixed liquid 2 1 : mixing a cadmium-112 target chemical separation liquid with a cadmium bromide solution to form a mixed liquid. Step (B 2 Producing a cadmium hydroxide precipitate 2 2 ··taking a hydroxide solution and adding to the above mixture and stirring to produce a cadmium hydroxide precipitate, wherein the hydroxide solution may be a potassium hydroxide solution or It is a sodium hydroxide solution. Step (C 2 ) forms a cadmium-112 isotope 2 3 : The cadmium hydroxide sump material is transferred into a semi-automatic vacuum filtration system, and subjected to hydrazine and "washing" to recover the ore j-112 isotope. The ore-112 isotope recovered from the above two methods can be calcined into a solid oxidized ore, or dissolved in a cyanide solution and an assay solution to form a cadmium-112 target plating solution, and the cadmium-112 isotope recovery The rate can reach above 98%, the purity can reach about 99%, and it is easy to store. In summary, the method for recovering cadmium-112 isotope of the present invention is to recycle and recycle cadmium-112 isotope to recover the recovery rate and 98% purity In addition, it can also save the cost of purchasing raw materials and reduce the cost of nuclear medicine, so that the invention can be made more progressive, more practical, and more suitable for users. It has indeed met the requirements of the invention patent application. It is only the preferred embodiment of the present invention, and the scope of the present invention is not limited thereto; therefore, the simple equivalent changes and modifications made in accordance with the scope of the invention and the description of the invention should still be It is within the scope of the present invention. 200848371 BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic flow chart of a first embodiment of the present invention. Fig. 2 is a flow chart showing a second embodiment of the present invention. [Main component symbol description] Step (A 1 )~(D 1 ) 1 1~1 4 Step (A2)~(C2)21~23
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW96121583A TW200848371A (en) | 2007-06-14 | 2007-06-14 | Method of recovering Cd-112 isotope |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW96121583A TW200848371A (en) | 2007-06-14 | 2007-06-14 | Method of recovering Cd-112 isotope |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200848371A true TW200848371A (en) | 2008-12-16 |
| TWI342867B TWI342867B (en) | 2011-06-01 |
Family
ID=44823823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW96121583A TW200848371A (en) | 2007-06-14 | 2007-06-14 | Method of recovering Cd-112 isotope |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200848371A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI426051B (en) * | 2011-10-27 | 2014-02-11 | Atomic Energy Council | Method of fabricating radioactive isotope of indium-111 |
-
2007
- 2007-06-14 TW TW96121583A patent/TW200848371A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI426051B (en) * | 2011-10-27 | 2014-02-11 | Atomic Energy Council | Method of fabricating radioactive isotope of indium-111 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI342867B (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| von Schulthess et al. | Integrated PET/CT: current applications and future directions | |
| Dunphy et al. | In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of 18F-(2 S, 4 R)-4-fluoroglutamine | |
| Öberg et al. | Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours | |
| Comoretto et al. | Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT | |
| Niccoli Asabella et al. | [Retracted] The Copper Radioisotopes: A Systematic Review with Special Interest to 64 Cu | |
| US6638490B2 (en) | Production of high specific activity copper-67 | |
| CN105750538A (en) | Processes, systems, and apparatus for cyclotron production of technetium-99m | |
| Follacchio et al. | Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings | |
| Brugarolas et al. | Fifty years of radiopharmaceuticals | |
| Choiński et al. | Prospects for the production of radioisotopes and radiobioconjugates for theranostics | |
| CN106146472A (en) | A kind of A Lishatan compound of double action | |
| CN106415734A (en) | Production of 43Sc radionuclide and radiopharmaceuticals thereof for use in positron emission tomography | |
| TW200848371A (en) | Method of recovering Cd-112 isotope | |
| Piccardo et al. | Role of 64CuCl2 PET/CT in detecting and staging Muscle-Invasive bladder cancer: comparison with Contrast-Enhanced CT and 18F-FDG PET/CT | |
| Hall et al. | PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? | |
| JP4792431B2 (en) | Cadmium-112 isotope recovery method | |
| Türler | Matched pair theranostics: Medicinal Chemistry and Chemical Biology highlights | |
| US8043584B2 (en) | Method of recycling Cd-112 isotope | |
| EP2014778A2 (en) | Method of recycling Cd-112 isotope | |
| Grammaticos | Pioneers of nuclear medicine, Madame Curie. | |
| CN113861254A (en) | A kind of tumor PET imaging agent 68Ga-NOTA-ADG and its preparation method and application | |
| Xiaoxiang et al. | 68Ga-DOTATATE and 18F-FDG PET/CT dual-modality imaging enhances precision of staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms | |
| TW200800372A (en) | Process for producing radioisotope Tl-201 | |
| CN118155901A (en) | A method for preparing high specific activity 51Cr radionuclide | |
| CN113372399A (en) | A kind of fluorine [ 2 ]18F]Synthesis method of deoxyglucose injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |